Ipsos Healthcare Launches Hyperlipidemia Therapy Monitor

mia.burns October 25, 2013 London, UK – Ipsos Healthcare, the global healthcare division of Ipsos, has announced the launch of its syndicated Hyperlipidemia Therapy Monitor – ...

UPDATED: Bristol-Myers adds promising survival update on breakthrough cancer program

John Carroll Bristol-Myers Squibb has added a few more brushstrokes to the very promising picture that's emerging from early-stage studies of nivolumab, a top PD-1 checkpoint receptor ...

IAPO Patient Solidarity Day Film to Launch

mia.burns 24 October 2013 London, United Kingdom     Official Film launch: 6 Days to go until Patient Solidarity Day 2013   On 30 October 2013, patient advocates across Africa ...

Hopkins study reports setback in HIV/AIDS cure

Emily Mullin New research suggests that a cure for HIV/AIDS may be much further off that scientists believed, underscoring the need for different drug approaches. FierceBiotech News

Biogen’s Tecfidera snaps up managed care coverage en route to blockbuster sales

Carly Helfand Biogen Idec's MS pill Tecfidera has had no problem taking the market by storm since its launch in April. And armed with new reimbursement data, analysts now say more ...

Karo Bio Announces 2013 Interim Report

mia.burns INTERIM REPORT JANUARY-SEPTEMBER 2013 The January–September period and the third quarter 2013 in brief Net sales amounted to MSEK 37.4 (24.6), whereof the third quarter ...

Zogenix shares soar after FDA approves first pure hydrocodone pain med

John Carroll The FDA has approved Zogenix's pain med Zohydro ER, sending its shares soaring on the reversal of fortunes for a drug that had been rejected by an expert panel late ...

FDA to Issue Final Sofosbuvir by Dec. 8

mia.burns – Final FDA Decision on Sofosbuvir Anticipated by December 8, 2013 – FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. 25, 2013– Gilead Sciences, Inc. ...

Gilead sweeps FDA panel vote for pioneering hep C drug sofosbuvir

John Carroll There were no big surprises for Gilead's $ 11 billion hepatitis C drug sofosbuvir at today's FDA panel review. The therapy, which promises to help create an entirely ...

J&J gets FDA panel backing for simeprevir in hot race for hep C drug

Eric Palmer An FDA panel voted 19-0 to recommend its simeprevir, an NS3/4A protease inhibitor that promises to treat the most common genotype of chronic hepatitis C. FiercePharma News

Atheris and Debiopharm Group to collaborate

barbara.lempert Atheris and Debiopharm Group™ to collaborate for the lead optimization of Debio 0826 using a “Reverse-Discovery” strategy Geneva and Lausanne, Switzerland – ...

Armed-antibody successes inspire a burst of new building projects, industry deals

John Carroll The rapid success of Roche's breast cancer drug Kadcyla following the breakthrough approval of Seattle Genetics' Adcetris helped make antibody-drug conjugates one ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS